{"id":"NCT04043806","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study Evaluating the Long-term Safety of VX-445 Combination Therapy","officialTitle":"A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-09","primaryCompletion":"2022-12-14","completion":"2022-12-14","firstPosted":"2019-08-02","resultsPosted":"2023-07-06","lastUpdate":"2023-07-06"},"enrollment":458,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"This study evaluated the long-term safety and tolerability of elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA) triple combination (TC) treatment in participants with cystic fibrosis (CF).","primaryOutcome":{"measure":"Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"From Baseline through Week 100","effectByArm":[{"arm":"ELX/TEZ/IVA","deltaMin":435,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":97,"countries":["United States","Australia","Canada","Denmark","Germany","Ireland","Israel","Poland","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["37983082","33331662"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":75,"n":457},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Headache","Upper respiratory tract infection","Sputum increased"]}}